Details of the Drug

General Information of Drug (ID: DMN45IC)

Drug Name
AFM13
Indication
Disease Entry ICD 11 Status REF
Hodgkin lymphoma 2B30 Phase 2 [1]
Mycosis fungoides 2B01 Phase 2 [2]
Peripheral T-cell lymphoma 2A90.C Phase 2 [2]
Lymphoma 2A80-2A86 Phase 1/2 [3]
Drug Type
Antibody
Cross-matching ID
DrugBank ID
DB17404
TTD ID
DZM2L1
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Immunoglobulin gamma Fc receptor IIIA (FCGR3A) TTIFOC0 FCG3A_HUMAN Not Available [4]
Lymphocyte activation antigen CD30 (TNFRSF8) TT2GM5R TNR8_HUMAN Not Available [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02321592) GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04101331) Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of Affimed Therapeutics.